Biopath.Med SPRL
Biopath.Med reported total assets of 569,374 € at the end of the 2025 financial year (annual accounts filed with the NBB on 17 Jun 2026).
The score of Biopath.Med shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2022 → 2025: Equity -15 % Total assets -15 %
Accounts of the company itself (not consolidated).
The full file covers 10 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Biopath.Med's annual accounts
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net result | −10,505 € | ||||
| Equity | 561,200 € | ||||
| Cash | 110,378 € | ||||
| EBITDA | −19,566 € | ||||
| Total assets | 569,374 € |
Filed annual accounts
- Year ended 31 Dec 2025filed on 17 Jun 2026
- Year ended 31 Dec 2024filed on 26 Jun 2025
- Year ended 31 Dec 2023filed on 20 Jun 2024
- Year ended 31 Dec 2022filed on 12 Jun 2023
- Year ended 31 Dec 2021filed on 05 Jul 2022
Biopath.Med's financial analysis
- Solvency98.6%sector median: 64.5%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Biopath.Med
Biopath.Med's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0543.629.372
- VAT number
- BE0543629372
- Peppol
- Registered · 0208:0543629372 · as of 10 Nov 2026
- Legal form
- SPRL
- Incorporated
- 23 Dec 2013
- Registered office
- 1350 Orp-Jauche
- Latest accounts
- 2025 · filed on 17 Jun 2026
- Activity
- Medical specialists activities (NACE 86220)
Biopath.Med (SPRL) has been based in Orp-Jauche since 2013, active in: medical specialists activities. For 2025, it reports a net loss of 10,505 € and equity of 561,200 €; its revenue is not published. Its solvency stands at 98.6%, above the median of its sector (64.5%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Biopath.Med
Companies in the same business, of comparable size and area, outside its group.
- JMB Farming Activities of holding companies Hoogstraten · balance sheet 957,418 €
- Financiere Schroder Activities of holding companies Amel · balance sheet 511,711 €
- Odette Celeste Activities of holding companies Herenthout · balance sheet 569,544 €
- Stanwick Partners Activities of holding companies Lochristi · balance sheet 569,546 €
- BEST Activities of holding companies Machelen (Brab.) · balance sheet 568,455 €
- Abmw Consulting Activities of holding companies Zaventem · balance sheet 570,438 €
- Taurus Real Estate Invest Activities of holding companies Ghent · balance sheet 568,236 €
- Peter Telders Business and other management consultancy activities Antwerp · balance sheet 567,856 €
Frequently asked questions about Biopath.Med
What is the revenue of Biopath.Med?
Biopath.Med files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Biopath.Med?
In Belgium, the VAT number is the company number prefixed with BE: BE0543629372 for Biopath.Med, if the company is VAT-registered. Its company number (CBE) is 0543.629.372.
Where is the registered office of Biopath.Med?
According to the CBE register, the registered office of Biopath.Med is in 1350 Orp-Jauche.
What is the equity of Biopath.Med?
At the close of the 2025 financial year, the equity of Biopath.Med amounts to 561,200 €, a solvency of 98.6% of total assets.
Who manages Biopath.Med?
The register lists 2 active mandates at Biopath.Med. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
The full file of Biopath.Med
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →